Calidi Biotherapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $45,000 | — |
| Selling, general & administrative | $10.5M | $12.9M | $16.0M | $15.9M | — |
| Research and development | $9.7M | $8.9M | $13.0M | $7.3M | — |
| Operating expenses | $20.2M | $21.8M | $29.0M | $23.2M | — |
| Operating income | -$20.2M | -$21.8M | -$29.0M | -$23.1M | — |
| Pretax income | -$20.0M | -$22.2M | -$29.2M | -$25.4M | — |
| Income tax expense | $15,000 | $14,000 | $16,000 | $11,000 | — |
| Net income | -$19.9M | -$22.1M | -$29.2M | -$25.4M | — |
| Balance Sheet | |||||
| Cash and equivalents | — | $9.6M | — | — | $1.1M |
| Current assets | $6.3M | $10.2M | $4.3M | $786,000 | $1.5M |
| Total assets | $8.9M | $14.2M | $10.0M | $2.6M | $231.8M |
| Current liabilities | $3.9M | $9.5M | $10.2M | $43.0M | $410,985 |
| Total liabilities | $5.1M | $12.2M | $18.3M | $43.4M | $16.5M |
| Total debt | $690,000 | $3.8M | $2.9M | $5.4M | — |
| Stockholders' equity | $3.8M | $1.5M | -$8.2M | -$50.4M | -$31.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$21.3M | -$19.7M | -$27.0M | -$13.2M | — |
| Depreciation and amortization | $1.7M | $402,000 | $392,000 | $260,000 | — |
| Stock-based compensation | $2.1M | $3.0M | $4.8M | $4.5M | — |
Shares outstanding 19.3M · Free float 17.8%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.